NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors

Guo-Bo Li, Martine I. Abboud, Jürgen Brem, Hidenori Someya, Christopher T Lohans, Shen-Yong Yang, James Spencer, David W Wareham, Michael A McDonough, Christopher J Schofield

Research output: Contribution to journalArticle (Academic Journal)peer-review

50 Citations (Scopus)
117 Downloads (Pure)


There are no clinically useful inhibitors of metallo-β-lactamases (MBLs), which are a growing problem because they hydrolyse almost all β-lactam antibacterials. Inhibition by most reported MBL inhibitors involves zinc ion chelation. A structure-based virtual screening approach combined with NMR filtering led to the identification of inhibitors of the clinically relevant Verona Integron-encoded MBL (VIM)-2. Crystallographic analyses reveal a new mode of MBL inhibition involving binding adjacent to the active site zinc ions, but which does not involve metal chelation. The results will aid efforts to develop new types of clinically useful inhibitors targeting MBLs/MBL-fold metallo-enzymes involved in antibacterial and anticancer drug resistance.
Original languageEnglish
Pages (from-to)928-937
Number of pages10
JournalChemical Science
Issue number2
Early online date14 Dec 2016
Publication statusPublished - 1 Feb 2017


Dive into the research topics of 'NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors'. Together they form a unique fingerprint.

Cite this